argenx (ARGX) Stock: Buy, Sell, or Hold?
ARGX - argenx SE American Depositary Shares
$984.39
0.35 (0.04%)
â˛
5d:
-6.56%
30d:
+12.37%
90d:
+9.51%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 29, 2026
Get Alerted When ARGX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: ARGX is fairly priced but lacks strong directional signals. At -2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: ARGX is fairly priced but lacks strong directional signals. At -2.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$1913.74
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$1188.28
17.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ARGX is currently trading at $984.39, which is considered fair relative to its 30-day fair value range of $901.47 to $1050.73. The stock's valuation (Forward PE: 25.0) is in line with its historical norms (27.2). Remarkably, the market is currently pricing in an annual earnings decline of 2.7% over the next few years. This pessimistic expectation contrasts with the company's recent 95.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $981.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ARGX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1179.74 (+19.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ARGX is in a strong uptrend. The price is currently testing key support at $981.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ARGX scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $1179.74 (+19.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$901.47 -
$1050.73
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($1179.74)
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$901.47 -
$1050.73
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$981.74
Resistance Level
$1072.75
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
25.04
Wall Street Target
$1179.74
(+19.8%)
Revenue Growth (YoY)
59.3%
Earnings Growth (YoY)
95.2%
Profit Margin
32.3%
Valuation Discount vs History
-2.7% cheaper
PE vs Historical
25.0 vs 27.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.7%
(market-implied from PE analysis)
1-Year Target
$957.81
(-3%)
2-Year Target
$931.95
(-5%)
3-Year Target
$906.79
(-8%)
3-Yr Target (if PE normalizes)
(PE: 25â27)
$984.93
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 25.0, Growth: 35.4%)
$2443.20
(+148%)
Base:
(SPY PE: 20.2, Growth: 35.4%)
$1967.86
(+100%)
Bear:
(PE: 17.1, Growth: 35.4%)
$1672.68
(+70%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (25x PE) as earnings recover.
Trailing PE: 38.17 | Current EPS (TTM): $25.78
Bull Case
$1650.51
(+68%)
Analyst growth 52.5%, PE expands to 42.0
Base Case
$1500.47
(+52%)
Market implied 52.5%, PE stable at 38.2
Bear Case
$669.15
(-32%)
Severe decline -20.0%, PE contracts to 32.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 25.0 to 27.2
Stabilization Target:
$1069.22
(+8.6%)
PE Expansion Potential:
+8.6%
Share & Embed Analysis
Last updated: September 13, 2026 8:39 AM ET
Data refreshes hourly during market hours. Next update: 9:39 AM
Data refreshes hourly during market hours. Next update: 9:39 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARGX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 48 HOLD |
